Konstantin Zhernosekov

Part of Lonza Group AG, Tissue Engineering Technologies AG is a German company that manufactures bacterial and virus vaccines, toxoids, and analogous products. The company is based in Reutlingen City, Germany. The company was founded in 2000 by Hugo Hämmerle. The CEO is Detlef Schumann.

ArchiMed SAS (ArchiMed) is a private equity firm founded in 2014 by Cedric Berger, David Piccoli, and Vincent Guillaumot. The firm is headquartered in Lyon, France.

TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management.

Definiens AG is a holding company, which engages in the development and market of biomedical imaging and data analysis software solutions. The firm specializes in the design and manufacture of imaging software suites for drug discovery, development, and diagnostics applications. It engages in the custom image analysis projects for the biopharmaceutical industry, spanning drug discovery, translational research, and clinical research. It offers image analysis processing, integration and deployment, planning, and consulting services. The company was founded by Gerd Binnig in 1994 and is headquartered in Munich, Germany.

iTAC Software AG provides software solutions. It offers serves the automotive industry, medical technologies, metal processing industry, energy and utilities industry, and electronics industry. The firm's products are manufacturing execution system (MES) suite, embedded systems, smart devices and enterprise framework. The company was founded by Dieter Meuser, Volker Burch and Christine Lahnstein in 1998 and is headquartered in Montabaur, Germany.

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

ITM Isotope Technologies Munich SE is a leading radiopharmaceutical biotech company based in Garching, Germany. The German company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and supply. ITM Isotope Technologies Munich SE strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life. ITM is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. With a broad precision oncology pipeline, including two phase III studies, ITM combines high-quality radioisotopes with a range of targeting molecules. The company was founded in 2004, and Steffen Schuster has been the CEO since 2011.